Carlsbad-based Tyra Biosciences , Inc. announced a change in its Board of Directors, according to a recent SEC filing. On Monday, Nina Kjellson resigned from her position on the Board and the ...

UBS analyst Eliana Merle initiated coverage of Tyra Biosciences (TYRA) with a Buy rating and $28 price target Tyra Biosciences is a clinical-stage biotech company with a drug, TYRA-300 ...

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology.

(RTTNews) - Tyra Biosciences (TYRA), a clinical-stage biotechnology company, on Friday announced that it has received U.S. FDA clearance for its Investigational New Drug or IND application for ...